Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis

Blood Cancer J. 2017 Sep 15;7(9):e607. doi: 10.1038/bcj.2017.89.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Bispecific / administration & dosage*
  • Chromosomes, Human, Pair 1* / genetics
  • Chromosomes, Human, Pair 1* / metabolism
  • Chromosomes, Human, Pair 11* / genetics
  • Chromosomes, Human, Pair 11* / metabolism
  • DNA-Binding Proteins* / genetics
  • DNA-Binding Proteins* / metabolism
  • Female
  • Histone-Lysine N-Methyltransferase* / genetics
  • Histone-Lysine N-Methyltransferase* / metabolism
  • Humans
  • Myeloid-Lymphoid Leukemia Protein* / genetics
  • Myeloid-Lymphoid Leukemia Protein* / metabolism
  • Oncogene Proteins, Fusion* / genetics
  • Oncogene Proteins, Fusion* / metabolism
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / blood
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / pathology
  • Transcriptional Elongation Factors* / genetics
  • Transcriptional Elongation Factors* / metabolism
  • Translocation, Genetic*

Substances

  • Antibodies, Bispecific
  • DNA-Binding Proteins
  • KMT2A protein, human
  • Oncogene Proteins, Fusion
  • Transcriptional Elongation Factors
  • Myeloid-Lymphoid Leukemia Protein
  • AFF1 protein, human
  • blinatumomab
  • Histone-Lysine N-Methyltransferase